

ASX Announcement

Race investor briefing invitation

22 July 2022 - Race Oncology Limited ("Race") is pleased to invite shareholders and potential investors to attend a special online investor briefing.

Through the briefing, CEO Phil Lynch and CSO, Dr Daniel Tillett will present an overview of the Quarterly report with focus on recent Zantrene data and other progress. The formal presentation will be followed by an interactive Q+A session.

Briefing details

Date/time: Wednesday 27 July from 6pm Australian Eastern Standard Time (AEST)

Format: Online webinar

Registration link:

https://us02web.zoom.us/webinar/register/WN_fA3SKQMvSb-G6Za5bRzyvg

Once the registration form is completed, investors will receive a confirmation email detailing how to access the briefing.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com



Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au